secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0000950170-24-130553
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance
--------------------------------------------------------------------------------

- Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.
- Net loss Q4 $28.8M ($1.36/shr); full-year $116.0M ($5.48/shr) vs $133.8M prior year.
- Cash & securities $248.2M at Sept 30, 2024; runway expected into fiscal 2027.
- RSVPEDs zelicapavir Phase 2 topline data due December 2024; EDP-323 Phase 2a met endpoints (p<0.0001).
- Immunology expansion: KIT inhibitor EPS-1421 nominated; new STAT6 discovery program initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/0000950170-24-130553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-20241125.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-130553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer